<SEC-DOCUMENT>0001818382-24-000153.txt : 20240813
<SEC-HEADER>0001818382-24-000153.hdr.sgml : 20240813
<ACCEPTANCE-DATETIME>20240813070456
ACCESSION NUMBER:		0001818382-24-000153
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240809
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240813
DATE AS OF CHANGE:		20240813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		241198733

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20240809.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0cb9eab6-f8b7-4089-bdf0-343500258a80,g:47541866-5bbd-4967-ae6e-c91a45891371,d:9d2490ef6f4c47dbae3decd70047abe9-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20240809</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20240809.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-09</xbrli:startDate><xbrli:endDate>2024-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-09</xbrli:startDate><xbrli:endDate>2024-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-09</xbrli:startDate><xbrli:endDate>2024-08-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9d2490ef6f4c47dbae3decd70047abe9_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160; <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 9, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Humacyte, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.810%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9d2490ef6f4c47dbae3decd70047abe9_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;13, 2024, Humacyte, Inc. (the &#8220;Company&#8221;) issued a press release regarding its financial results for its fiscal second quarter ended June&#160;30, 2024. A copy of this press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit 99.2 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01. Other Events.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2024, the Company issued a press release announcing that the U.S. Food and Drug Administration will require additional time to complete its review of the Company&#8217;s Biologics License Application seeking approval of the Company&#8217;s acellular tissue engineered vessel in the vascular trauma indication. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div id="i9d2490ef6f4c47dbae3decd70047abe9_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20240809xexx991.htm">Press release, dated August 9, 2024.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20240813xexx992.htm">Press release, dated August 13, 2024.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i9d2490ef6f4c47dbae3decd70047abe9_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  August 13, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20240809xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic5d5ed46485f41b7b2dafc3d744a8474_1"></div><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:145%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="image_0b.jpg" src="image_0b.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:316px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">) BLA for the Treatment of Vascular Trauma</font></div><div style="margin-top:14pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.89pt">2nd quarter conference call to be held Tuesday, August 13th, at 8&#58;30 a.m. ET -</font></div><div style="margin-top:14pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DURHAM, N.C., August 9, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> tissues at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication. The ATEV trauma program BLA was submitted to FDA in December 2023, and the FDA granted a Priority Review in February 2024 and assigned a PDUFA date of August 10, 2024. In a phone call from FDA CBER leadership today, the Company was informed that the FDA required additional time to complete its review.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;We received a call from FDA CBER leadership this afternoon apologizing to us and stating that additional time was required for review.&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;FDA leadership noted that Humacyte&#8217;s ATEV is a first-in-class product, and that Priority Review had been granted, which allows only a six-month review cycle, as compared to the standard ten-month review cycle for most products. During the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing, including post-marketing and labeling discussions. Based on these interactions, we are confident in the approvability of the ATEV in treating vascular trauma. The FDA leadership expressed an apology for their inability to complete the review by the PDUFA date, and currently we do not yet have a revised action date.&#8221;</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ATEV is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair. While harvesting vein from a trauma patient takes valuable surgical time, ATEV is available off the shelf, and does not require further injuring the patient to obtain the needed vascular repair material. Humacyte&#8217;s BLA included positive results from the V005 pivotal Phase 2&#47;3 clinical study, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program. ATEV was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents. It was utilized by vascular and trauma surgeons in Level 1 Trauma centers throughout the U.S. and Israel to repair severe limb-threatening and life-threatening injuries, and in front-line hospitals in Ukraine to treat war injuries. In both the civilian and military clinical studies, ATEV was observed to have high rates of patency, or blood flow, and low rates of amputation and infection.</font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call Information</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Management will be available during its 2nd quarter 2024 financial report and business update conference call, details ss follows&#58;</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">August 13, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8&#58;30 AM Eastern Time</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1-877-704-4453 (U.S. Investors Dial)<br>1-201-389-0920 (International Investors Dial)<br>13747913 (Conference ID)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Call me</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> Feature&#58; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Click Here</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Humacyte</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte&#8217;s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review with a PDUFA date of August 10, 2024. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte&#8217;s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, the expected PDUFA date for our ATEV in vascular trauma repair&#59; the statements regarding the initiation, timing, progress, and results of our preclinical and </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">clinical trials, including our BVP program&#59; the anticipated characteristics and performance of our ATEVs and the BVP&#59; our ability to successfully complete, preclinical and clinical trials for our ATEVs and the BVP&#59; the anticipated benefits of the BVP relative to existing alternatives&#59; the anticipated commercialization of our ATEVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those described under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2023, filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br>Joyce Allaire<br>LifeSci Advisors LLC<br>+1-617-435-6602<br></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">investors&#64;humacyte.com</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Humacyte Media Contact&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br>Rich Luchette<br>Precision Strategies<br>+1-202-845-3924<br></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">rich&#64;precisionstrategies.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><br></font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;humacyte.com</font></div><div style="margin-top:10pt;text-align:center"><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>huma-20240813xexx992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic7e13fb72ec44dfb99692cf6aeb0f7fd_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.2</font></div><div style="margin-top:10pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"></div><div style="margin-top:16pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Quarter 2024 Financial Results and Business Update</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-FDA requires additional time to complete its review of ATEV&#8482; (acellular tissue engineered vessel) BLA for the Treatment of Vascular Trauma-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-Reported Positive Topline Results from Phase 3 Trial of ATEV in Hemodialysis Access-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-ATEV Received Third Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA in Advanced Peripheral Artery Disease-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Conference call and live webcast at 8&#58;30 a.m. ET today-</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DURHAM, N.C., August&#160;13, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tissue at commercial scale, today announced financial results for the second quar</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ter ended June&#160;30, 2024 and highlighted recent accomplishments. </font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We were surprised to be notified by the FDA that they will require additional time to complete their review of the BLA for our ATEV (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acellular tissue engineered vessel) </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in vascular trauma,&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA leadership noted that Humacyte&#8217;s ATEV is a first-in-class product, and that Priority Review had been granted, which involves only a six-month review cycle, as compared to the standard ten-month review cycle for most products. During the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing, including post-marketing and labeling discussions. Based on these interactions, we are confident in the approvability of the ATEV in treating vascular trauma, although we currently do not yet have a revised action date.</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The ATEV continues to make significant progress in its other investigational indications, including in hemodialysis access,&#8221; continued Dr. Niklason. &#8220;We were pleased to announce positive top-line results from the V007 Phase 3 clinical trial in patients with end-stage renal disease, in which the ATEV was observed to have superior functional patency over current standard of care. In addition, the ATEV received its third RMAT designation from the FDA, specifically in advanced peripheral artery disease. This serves as a recognition from the Agency that Humacyte&#8217;s ATEV may provide an important therapeutic option for patients with advanced arterial disease in their legs, who are facing potential amputation.</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are proud that the ATEV&#8217;s broad potential continues to be recognized and look forward to presenting additional results across our pipeline at upcoming medical meetings.&#8221; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Recent Corporate Highlights</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ATEV (acellular tissue engineered vessel)</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">FDA extension of time to complete review of BLA for ATEV in the Treatment of Vascular Trauma</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; On August 9, 2024, in a phone call, Center for Biologics Evaluation and Research (CBER) leadership from the U.S. Food and Drug Administration (FDA) notified the Company that the FDA will require additional time to complete its review of the Company&#8217;s Biologics License Application (BLA) for the ATEV in the vascular trauma indication. The ATEV trauma BLA was submitted to FDA in December 2023, FDA granted a Priority Review in February 2024, and assigned a PDUFA date of August 10, 2024. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Positive Topline Results of ATEV in Hemodialysis Access</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In July 2024, Humacyte reported positive topline results from the V007 Phase 3 clinical trial (NCT03183245) of the ATEV in arteriovenous (AV) access for patients on hemodialysis. The V007 trial is prospective, multi-center, randomized clinical study in 242 hemodialysis patients in the United States. Participants were randomly assigned to receive either the ATEV or an AV fistula for hemodialysis access and are being followed for up to 24 months. In the trial, the ATEV was observed to provide superior functional patency at six and 12 months (co-primary endpoints&#59; </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">p</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#61;0.0071) compared to autogenous fistula, which is the current standard of care for hemodialysis patients. Patients on ATEV also achieved a significantly longer duration of hemodialysis using the ATEV over the first 12 months, as compared to autogenous fistula (p&#61;0.0162). Humacyte anticipates that detailed results from the trial will be presented at upcoming medical meetings. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">ATEV Received Third Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In July 2024, the FDA granted RMAT designation of the ATEV for patients with advanced peripheral artery disease (PAD). This RMAT designation is granted at the same time as FDA cleared a new Investigational New Drug (IND) application for the PAD indication. This is the third RMAT designation granted by the FDA for Humacyte&#8217;s ATEV, in addition to previous RMAT designations for vascular trauma repair and AV access in hemodialysis.</font></div><div style="margin-top:10pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical and Scientific Publications and Presentations</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">PAD Publication&#58;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, Dr. Todd Rasmussen and colleagues at the Mayo Clinic in Rochester MN published outcomes of arterial bypass using the ATEV in patients with chronic limb ischemia (severe PAD).</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this paper, appearing in the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Vascular Surgery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June, all patients treated with the ATEV for severe PAD had no suitable vein of their own for bypass, and were treated under an investigator-sponsored protocol.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outcomes for ATEV patency (or blood flow) and limb salvage in patients with severe PAD and no vein were compared to historical control patients, having similar disease but receiving a bypass using their own vein at the Mayo Clinic.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mayo investigators reported that patency and limb salvage were similar for patients receiving ATEV, and patients receiving bypass with their own vein.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This result highlights the potential impact that Humacyte&#8217;s ATEV may have on patients suffering from severe PAD and having no vein of their own to perform a bypass operation.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Presentations Highlighting Advancement of Diabetes Program </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; In June 2024, Humacyte presented positive r</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">esults from ongoing preclinical studies supporting the potential of Humacyte&#8217;s BioVascular Pancreas (BVP&#8482;) product candidate to enable the delivery and survival of insulin-producing islets as a potential treatment for type 1 diabetes&#58; </font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">At a presentation at the Breakthrough T1D (formerly, JDRF) Beta Cell Consortium Meeting in New York City, scientists presented data in which stem cell-derived islets, manufactured at Humacyte, were observed to restore normal blood sugar in diabetic mice. In the mice, the stem cell-derived islets survived and continued to produce insulin, with no evidence of adverse safety events from the stem cell-derived islets. These experiments were performed in collaboration with the Diabetes Research Institute (DRI) at the University of Miami.</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">At the American Diabetes Association annual meeting in Orlando, Florida, Humacyte reported successful implantation of BVPs into non-human primate recipients. In the study, also performed in collaboration with the DRI, primate BVP implants showed islet survival and continued insulin production throughout the three-month duration of the study. Islets also developed capillaries to support survival of the insulin-producing cells. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">CABG Preclinical Remodeling Results </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical six-month studies have been conducted in non-human primates to support the planned advancement of the small-diameter ATEV into human clinical trials in coronary artery bypass graft (CABG) surgery. Humacyte has observed remodeling of the ATEV to a diameter that closely matches that of the native coronary vessels in non-human primates, which is an outcome not observed with any other conduit and highlights the potential adaptability of the ATEV in vivo.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These promising results of ATEV patency and remodeling were presented at the Tissue Engineering and Regenerative Medicine (TERM-2024) Conference on June 11-12, 2024.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strengthened Board of Directors</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; In July 2024, Humacyte announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and distinguished health system and academic physician Dr. Keith Anthony (Tony) Jones to the Company&#8217;s Board of Directors.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Financial Highlights</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There was no revenue for either the second quarter of 2024 or the second quarter of 2023, and there was no revenue for the six months ended June 30, 2024 and 2023.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were $23.8 million for the second quarter of 2024, compared to $20.5 million for the second quarter of 2023, and were $45.0 million for the six months ended June&#160;30, 2024, compared to $37.8 million for the six months ended June&#160;30, 2023. The current-period increases resulted primarily from increased materials and personnel expenses to support expanded research and development initiatives and our clinical trials, including the expansion of manufacturing activities and support of the FDA review of the BLA in vascular trauma.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $5.7 million for the second quarter of 2024, compared to $6.2 million for the second quarter of 2023, and were $11.1 million for the six months ended June&#160;30, 2024, compared to $11.4 million for the six months ended June&#160;30, 2023. The slight decreases during 2024, resulted primarily from a decrease in non-cash stock compensation expense, partially offset by increased personnel expenses and increased professional fees.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net income (expense) was net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $27.2 million for the second quarter of 2024, compared to net income of $4.0 million for the second quarter of 2023, and other net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $32.5 million for the six months ended June&#160;30, 2024, compared to other net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $10.4 million for the six months ended June&#160;30, 2023. The increase in other net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the second quarter of 2024 and the six months ended June&#160;30, 2024 compared to 2023 resulted primarily from the non-cash remeasurement of the contingent earnout liability associated with the Company&#8217;s August 2021 merger with Alpha Healthcare Acquisition Corp.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was $56.7 million for the second quarter of 2024, compared to $22.7 million for the second quarter of 2023, and net loss was $88.6 million for the six months ended June&#160;30, 2024, compared to $59.7 million for the six months ended June&#160;30, 2023. The current-period </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net loss resulted primarily from the non-cash remeasurement of the contingent earnout liability, and operating expense increases, described above.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash and cash equivalents of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$93.6 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of June&#160;30, 2024. Total net cash </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $13.1 million for the first six months of 2024, compared to net cash </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">used </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $35.2 million for the first six months of 2023. The increase in net cash </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> resulted primarily from the receipt of approximately $43.0 million in net proceeds from an underwritten public offering of Humacyte&#8217;s common stock in March 2024, and $20 million in proceeds from an additional draw under its funding arrangement with Oberland Capital Management.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.099%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Humacyte Second Quarter 2024 Financial Results Corporate Update</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tuesday, August 13, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;30 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453<br>International&#58; 1-201-389-0920<br>Conference ID #&#58; 13747913</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Call me</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Feature (avoid waiting for operator)&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Click Here</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Humacyte</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte&#8217;s initial product candidates, a portfolio of ATEVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. A Biologics License Application for the ATEV in the vascular trauma indication is currently under review by the FDA and was granted Priority Review. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte&#8217;s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, the outcome of the FDA&#8217;s review of our BLA seeking approval of the ATEV in the vascular trauma indication&#59; the statements regarding the initiation, timing, progress, and results of our preclinical and clinical trials, the anticipated characteristics and performance of our ATEV&#59; our ability to successfully complete preclinical and clinical trials for our ATEVs&#59; the anticipated benefits of the ATEV relative to existing alternatives&#59; the anticipated commercialization of our ATEVs and our ability to manufacture at commercial scale&#59; the implementation of our business model and strategic plans for our business&#59; and the timing or likelihood of regulatory filings, acceptances, and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those described under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2023, filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joyce Allaire</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeSci Advisors LLC</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1-617-435-6602</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">investors&#64;humacyte.com</font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Media Contact&#58;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rich Luchette</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision Strategies</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1-202-845-3924</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">rich&#64;precisionstrategies.com</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt"><font><br></font></div></div></div><div id="ic7e13fb72ec44dfb99692cf6aeb0f7fd_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:45.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,753&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,540&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,017&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,818&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,746&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,060&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,499&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,731&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,077&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,243&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29,499)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,731)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,077)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(49,243)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,571)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,164)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,564)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense) (net)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,593)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,318)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,164)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,482)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,432)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,663)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(22,706)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(88,559)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(59,675)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.78)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.58)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,174,681&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,361,501&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,710,344&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,312,785&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="ic7e13fb72ec44dfb99692cf6aeb0f7fd_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="margin-top:12pt"><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br>2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,563&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,448&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,110&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,278&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,820&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,791&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,536&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,313&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">815&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">138,281</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,005&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,490&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,950&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,340&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,757&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,443&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,080&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,916&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,078&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,123&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">166,568</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,677</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597,586&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(625,873)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537,314)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,287)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,546&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">138,281</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>huma-20240809.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0cb9eab6-f8b7-4089-bdf0-343500258a80,g:47541866-5bbd-4967-ae6e-c91a45891371-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20240809" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20240809">
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240809_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240809_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240809_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>huma-20240809_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0cb9eab6-f8b7-4089-bdf0-343500258a80,g:47541866-5bbd-4967-ae6e-c91a45891371-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20240809.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9dfeabb9-be05-4bfc-9196-e0e6c888ae68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntitiesTable_9dfeabb9-be05-4bfc-9196-e0e6c888ae68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75147df2-3e25-47ba-bbe4-82dd491bdcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_9dfeabb9-be05-4bfc-9196-e0e6c888ae68" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75147df2-3e25-47ba-bbe4-82dd491bdcd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_75147df2-3e25-47ba-bbe4-82dd491bdcd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75147df2-3e25-47ba-bbe4-82dd491bdcd1" xlink:to="loc_us-gaap_ClassOfStockDomain_75147df2-3e25-47ba-bbe4-82dd491bdcd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75147df2-3e25-47ba-bbe4-82dd491bdcd1" xlink:to="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5ca8f63b-ed0c-4862-b53d-1687d94333c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:to="loc_us-gaap_CommonStockMember_5ca8f63b-ed0c-4862-b53d-1687d94333c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6b93c9b1-9371-4c2e-8f46-df029e6c2ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:to="loc_us-gaap_WarrantMember_6b93c9b1-9371-4c2e-8f46-df029e6c2ac7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d822ea71-060c-48e8-88e3-bebeaca03cc9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_DocumentType_d822ea71-060c-48e8-88e3-bebeaca03cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9330eed5-ba1d-44df-bbd3-a5d59a75f48f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_DocumentPeriodEndDate_9330eed5-ba1d-44df-bbd3-a5d59a75f48f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a0e20586-f1bf-4af0-a949-3f16b5833d77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityRegistrantName_a0e20586-f1bf-4af0-a949-3f16b5833d77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2a966ecc-3a31-4e4a-b405-1c320e52a25c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2a966ecc-3a31-4e4a-b405-1c320e52a25c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_47611012-9e33-49a0-9b8d-29582f09dbdf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityFileNumber_47611012-9e33-49a0-9b8d-29582f09dbdf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ebbb994f-2385-48a5-bc61-53fa27d17d09" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityTaxIdentificationNumber_ebbb994f-2385-48a5-bc61-53fa27d17d09" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_14fd5897-e288-48c2-bca1-fd29ea5e658c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressAddressLine1_14fd5897-e288-48c2-bca1-fd29ea5e658c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4457d10b-f1b5-4909-9184-6a3402ae3653" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressCityOrTown_4457d10b-f1b5-4909-9184-6a3402ae3653" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c00cd6a8-ae57-40db-b768-8a0cb39b188e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressStateOrProvince_c00cd6a8-ae57-40db-b768-8a0cb39b188e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7cff221d-4298-4181-b837-0a2bb1310e89" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressPostalZipCode_7cff221d-4298-4181-b837-0a2bb1310e89" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9d11e545-046c-4949-9a8a-236e32ad4ce1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_CityAreaCode_9d11e545-046c-4949-9a8a-236e32ad4ce1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ac184cb8-a210-4075-821b-6d5dc13d8ed8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_LocalPhoneNumber_ac184cb8-a210-4075-821b-6d5dc13d8ed8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d70291b3-fd34-4bff-8b21-135535db94f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_WrittenCommunications_d70291b3-fd34-4bff-8b21-135535db94f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a475695d-123c-43a6-a9c6-3f36b3a48407" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_SolicitingMaterial_a475695d-123c-43a6-a9c6-3f36b3a48407" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a99463ba-b964-4c1c-8ccd-ec813a256908" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_PreCommencementTenderOffer_a99463ba-b964-4c1c-8ccd-ec813a256908" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f3c547a9-04eb-48a3-b2c6-cc42660c8b24" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f3c547a9-04eb-48a3-b2c6-cc42660c8b24" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_59e26406-6d48-4e05-aadb-15197c01fd4b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_Security12bTitle_59e26406-6d48-4e05-aadb-15197c01fd4b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a770474e-f4e2-4b64-926e-61fe7e5ab2b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_TradingSymbol_a770474e-f4e2-4b64-926e-61fe7e5ab2b7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ee66759e-6599-4d78-b838-4a4b328c9130" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_SecurityExchangeName_ee66759e-6599-4d78-b838-4a4b328c9130" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7696cb3c-2ac8-4ef7-ac35-0ae78db7782f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityEmergingGrowthCompany_7696cb3c-2ac8-4ef7-ac35-0ae78db7782f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6da7e321-6d93-4d3b-847d-f39b3184ea05" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityExTransitionPeriod_6da7e321-6d93-4d3b-847d-f39b3184ea05" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd53e1b3-36e2-42a9-a5cb-09a7bc45ae9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityCentralIndexKey_fd53e1b3-36e2-42a9-a5cb-09a7bc45ae9f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a737b8ab-2508-4dee-a3b3-79b678d64f35" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_AmendmentFlag_a737b8ab-2508-4dee-a3b3-79b678d64f35" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>huma-20240809_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0cb9eab6-f8b7-4089-bdf0-343500258a80,g:47541866-5bbd-4967-ae6e-c91a45891371-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ClassOfStockDomain_83dd7ca8-db65-4fe1-8e81-51645bb83376_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d623e19c-52c7-4122-8420-2115caaf56c4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_1d0eb36a-093e-423c-b396-3e9981b87de3_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a27733a9-4f8d-405b-97b2-339b8931ac03_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e6c9a828-c40d-4073-8808-ee1251944bd3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_65912b14-b1e6-40a3-a285-8b0bb2e947c3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_cb13cee6-07c6-4d03-b673-0ea6c9e95629_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2c7dd423-03b5-4712-ba72-5d3d36d82973_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_de436649-c2e0-4850-84ad-b010810258d8_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_32999c9f-7aa7-42b6-a025-2bbd9c0ba57e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e056917e-26ca-41b0-8755-f189c163f179_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6e1316bd-7f8d-4274-8ac5-4f967d632c4d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7e606834-93ca-4671-ab2d-3609f78d449b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f592613b-a636-43bf-b38f-c0cba6e21bc7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d61652e8-5548-4da9-bdfc-d20e5be01b44_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_b3629429-59ff-4144-ad0e-2944cb675598_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3bf15e7b-db2d-425f-9f5b-c1b3f5c06bb9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e9f60303-9baa-452c-9f2f-f186a0b865c6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7c87945c-6195-480a-a50a-2c7d5467696f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_14d39681-74ea-440c-8058-4ddbe980f849_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_856cadc5-ba5a-4d25-93bf-da059cd4174d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5807663e-3a8b-4494-94b7-05f59a28f710_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_473f9071-322a-42a3-b053-7f466dc2247e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_16db2f2a-4a1f-4e83-8af1-91fa15c991e4_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6af6e9a3-b941-4928-b8bc-337e8d822d63_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6967ccca-0373-4738-940e-f1ac48afbd17_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d9f999bc-a745-40ef-b90b-1ea62c4a2faf_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_659bca4f-eb32-4402-b183-d5399d3e32a1_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9337645b-6b14-4240-a0f6-b2492c4072a2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>huma-20240809_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0cb9eab6-f8b7-4089-bdf0-343500258a80,g:47541866-5bbd-4967-ae6e-c91a45891371-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20240809.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1fc0a867-d618-4073-9780-38eec28d6731" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_9dfeabb9-be05-4bfc-9196-e0e6c888ae68" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1fc0a867-d618-4073-9780-38eec28d6731" xlink:to="loc_dei_EntitiesTable_9dfeabb9-be05-4bfc-9196-e0e6c888ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75147df2-3e25-47ba-bbe4-82dd491bdcd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9dfeabb9-be05-4bfc-9196-e0e6c888ae68" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75147df2-3e25-47ba-bbe4-82dd491bdcd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75147df2-3e25-47ba-bbe4-82dd491bdcd1" xlink:to="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5ca8f63b-ed0c-4862-b53d-1687d94333c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:to="loc_us-gaap_CommonStockMember_5ca8f63b-ed0c-4862-b53d-1687d94333c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6b93c9b1-9371-4c2e-8f46-df029e6c2ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6b497173-0a2e-4f1c-b2b2-5ab5ca9cea1e" xlink:to="loc_us-gaap_WarrantMember_6b93c9b1-9371-4c2e-8f46-df029e6c2ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_9dfeabb9-be05-4bfc-9196-e0e6c888ae68" xlink:to="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d822ea71-060c-48e8-88e3-bebeaca03cc9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_DocumentType_d822ea71-060c-48e8-88e3-bebeaca03cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9330eed5-ba1d-44df-bbd3-a5d59a75f48f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_DocumentPeriodEndDate_9330eed5-ba1d-44df-bbd3-a5d59a75f48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a0e20586-f1bf-4af0-a949-3f16b5833d77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityRegistrantName_a0e20586-f1bf-4af0-a949-3f16b5833d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2a966ecc-3a31-4e4a-b405-1c320e52a25c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2a966ecc-3a31-4e4a-b405-1c320e52a25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_47611012-9e33-49a0-9b8d-29582f09dbdf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityFileNumber_47611012-9e33-49a0-9b8d-29582f09dbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ebbb994f-2385-48a5-bc61-53fa27d17d09" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityTaxIdentificationNumber_ebbb994f-2385-48a5-bc61-53fa27d17d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_14fd5897-e288-48c2-bca1-fd29ea5e658c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressAddressLine1_14fd5897-e288-48c2-bca1-fd29ea5e658c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4457d10b-f1b5-4909-9184-6a3402ae3653" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressCityOrTown_4457d10b-f1b5-4909-9184-6a3402ae3653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c00cd6a8-ae57-40db-b768-8a0cb39b188e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressStateOrProvince_c00cd6a8-ae57-40db-b768-8a0cb39b188e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7cff221d-4298-4181-b837-0a2bb1310e89" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityAddressPostalZipCode_7cff221d-4298-4181-b837-0a2bb1310e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9d11e545-046c-4949-9a8a-236e32ad4ce1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_CityAreaCode_9d11e545-046c-4949-9a8a-236e32ad4ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ac184cb8-a210-4075-821b-6d5dc13d8ed8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_LocalPhoneNumber_ac184cb8-a210-4075-821b-6d5dc13d8ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_d70291b3-fd34-4bff-8b21-135535db94f6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_WrittenCommunications_d70291b3-fd34-4bff-8b21-135535db94f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a475695d-123c-43a6-a9c6-3f36b3a48407" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_SolicitingMaterial_a475695d-123c-43a6-a9c6-3f36b3a48407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a99463ba-b964-4c1c-8ccd-ec813a256908" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_PreCommencementTenderOffer_a99463ba-b964-4c1c-8ccd-ec813a256908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_f3c547a9-04eb-48a3-b2c6-cc42660c8b24" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_f3c547a9-04eb-48a3-b2c6-cc42660c8b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_59e26406-6d48-4e05-aadb-15197c01fd4b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_Security12bTitle_59e26406-6d48-4e05-aadb-15197c01fd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a770474e-f4e2-4b64-926e-61fe7e5ab2b7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_TradingSymbol_a770474e-f4e2-4b64-926e-61fe7e5ab2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ee66759e-6599-4d78-b838-4a4b328c9130" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_SecurityExchangeName_ee66759e-6599-4d78-b838-4a4b328c9130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7696cb3c-2ac8-4ef7-ac35-0ae78db7782f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityEmergingGrowthCompany_7696cb3c-2ac8-4ef7-ac35-0ae78db7782f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6da7e321-6d93-4d3b-847d-f39b3184ea05" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityExTransitionPeriod_6da7e321-6d93-4d3b-847d-f39b3184ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fd53e1b3-36e2-42a9-a5cb-09a7bc45ae9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_EntityCentralIndexKey_fd53e1b3-36e2-42a9-a5cb-09a7bc45ae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a737b8ab-2508-4dee-a3b3-79b678d64f35" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_d601c969-6b15-45c1-8197-12d8a3f0971d" xlink:to="loc_dei_AmendmentFlag_a737b8ab-2508-4dee-a3b3-79b678d64f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  !!    #&" (   #D+^2&  !4HTE$051X7NV=
M!UQ45]J'36^;LKLI1A*3:&*2_4PV)KLQS6R,1I-8P!)+B!JQQ]Z58,7>L:&@
MH*)@+Z@(4A21)E($% N]]SJ]W/F.CAGQG)GAWCNW#;S/[__M[\LXY[UG"C/G
MF7O/.:T,@,TT5%$%Z;JT"&W\"6WX'LWIC<K3F]2!&]2GUJO/;%.%^ZKB3FFN
M1VG+<O441>&- 0       $#"M,)O &@CJZ9NQVDO^:E#=ZC/>ZI#MJO/;54'
M;5:?]5";A.'$.M7Q-:JCJU1'5JH.KT#_J[A\3%-P4X_7 @        !) L+
MAJH"?4JP-MQ;&>&M#O-Z6!BV6!.&0\M4 >XJ_Z6J8QO5-V)T>%T
MD!@@#,R0UU)IY[67?#47?307=JMI"L.QU;@P'%BL\ENH.KY.77@+M $
M  "0+B ,#"A(U<7L547MU7 E#/L6J/:ZJ2X<U.BT,+<!        D"(@#+30
M**G48'7,?DWT/@TF#.%LA6'_HOO"X.NJ/+!"U5 -S@        !(#A"&IE'6
M4?%'5;$'-/P)@\]\I?<\>641. ,        @+4 8FD!1IX\_(HOSYUT8=LU5
M[IR#G $64 (        D! B#-9 M7#E2'Q\@%T88O&<K/6?+%?5PG@$
M  "0"B ,%J'TAN03-5<"ZN(#!#K#@(1AYRRE]UPYWA4         $ D0!HND
MGZM).%@MO##LF*$\OEF)]P8         Q "$P3Q%UV4)!RNL"$,DG\*P?88\
M)PWV9P        #$!X3!#%J5/O%(*4_"<-"*,,RY+PR>TY4[IL&%20
M (#X@#"8X69$V=5#)2R$(9@[8=@V37DE1(OW#         "$!80!1UFO33I4
M( 5AV#8#3C(         (@/"@)-QOB3Q<"%=8=C%HS!LG:+,3H-M&0
M   Q 6%X"$I/)1\K^$L8RL41AID/A&'W?!7>10         0$!"&ARBX5IEX
M.,]68=C,F3!LF0I7)0$       !B L+P$.FG<YL0!C^6PG!T%2MAF*PLRH2K
MD@        #1 &%XB)3C62R$(6PGC\(0N$.-]Q(         A *$X0&R2D72
M$5(8:GD4AH46A6'[7\*P!39D         ,0#A.$!1=<JN!2&C=P(P]8I( P
M      " :(@C#)K*<.6=-?+T*8KK<Y6YN_6R+/P>8I 1FG=/&'*;%H8];(5A
M.6-AV#()A $        0#:&%@5(6-"3^TA#S>7WT5_717>HN?U=[N7M-5$_Y
M[4T&O0:_M[!</Y.#A"%)8L+@ 6<8         /$05!@H3;G\2C=9S'](8:B)
M^KGANKN!$G-%H/2S69:$(=Y?R9\P[/D3A $       "0*((*@RICG"SV$TO"
M4'VIC[HL$F\C('P(PTD0!@       ,">$4X8*'5Y0]Q'UH6A-GX\WDQ F K#
M14&$82O,80        #$0SAAT)8=E\=U-"<,W4S"4'6I'Z5MP%L*Q</"4"R*
M,'@1PK 9-GL&        Q$,X8= 4>=$1!IVB!&\I%.GG<B4H#+ / P
M " BP@F#KCKL+V'XS(HPZ+4RO*50W+E4*$%AV+M$B7<4         (1".&&@
M= IYPN=WA2'6HC#4ILS#FPE(15:M!(4A*4R+=Q0         A$(X84"HLY=9
M%P9M[76\C8!H5;K$HYD/"T,5.V$X8Z,PS+@O#)NGR%4*"N\H          B%
MH,) 41I%VC!+PJ L.((W$)S4$[F2$H;M,.,9        $!5!A0%!Z37JG#5U
MT5_71W_Y0!AB!ZE+@O&[BD%&:&&3PG"9K3 <82X,03XB[WX-        M'"$
M%@8CE*9"4WY6G>^CRM^CK8Y#_XW?0R3DU2IVPA"Z@WMAV#9%KE;@/00
M    (1%'&*1,RLD"0A@:1!&&_<M %P        "1 6' *;]3SYDP;& O#%NG
MR^NJ8+HS        (#(@#&9(.4Y#&'S9"L,R6L)P>(,*[Q8         " X(
M@QFJ\Q0)AXO8",,VCH1AIEP'NR\         $@"$P3PWSE=@PA#GSZ,P^+H^
M$ ;/6?);"3J\0P         @!B ,YM%KJ:1CW C#B;7,A"%HEQKO#0
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M"$.HKSHK18]7Y)GZ&NK(%M7,7@U3>\JF_""C(PRF3.W9$+A;K=7 9P$
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M&(*$%0:E7'QAF-+#_K9B &$      $: ,-@C]0WR?W>=;'QID E,G.=IFL^
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M0O)MO+HY0!B80E,8BDNK\):29-7FHV3G&>79M@-=IGJ</!?;(*-U249-;4/
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M0L-CK_?A::J5">D* Z655<;-*;\PLDEAR M959UQ 6_/A/1SZ:R%(<);K=.
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M_ D]J)G56]Y8&*;8)@PH*\?Q,@=?2$ 86-"M/ZUQV/?]7?&6DN3 L0MDY\F
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MC5>W 'IOA$8FCYFQA>EB3606KMZ/5^>3N\)@T)3H4_Y." #3W!4&JF05?@1
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MSK-M!\Y:["-7J/ ^B0<( ]!" 6$0A;5;CS_;5KC+0Q]OXS37?4]=O1SOQSU
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M7TK!NP4 O"&:,,@3^S$7AHE-"D,.(0S*JG+\V%P0?]#\I&?.A:&RF,?-J@$
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MD5_(RY75 , (T82!TFMDL=];%H:!G B#HJH,/S!W7#FFY548/*?)=?!K @
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MBJ^.'LQ0&!8^$(;SFY65>7A182F^K0OQ4M 1AH,/"\/^A8H[B;Q/T08
M    IDA(& QWYT#7RC+65$09A6$P?6&H3 _2:R5QZ;]>9[@5K0O:K*0I#/Y+
M% E!6K@,"0       ) FTA(&(SI93OV-#551OS8I#/FA2ZO2 [6*&KR$V"!M
MR$O5Q9U4!VY4FA6&PRL4D0'JVPF@"@       ("DD:(P&*&T,E79Y?I;/M57
MEU9<FO&7,$PIO;2HXLK6VHQ 1=EU7C=RYHJ&*JKXCCXW39>;JLM)U15GZ>LJ
B*/Q.         "!)_A^6L1,=D>"BX@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_0b.jpg
<TEXT>
begin 644 image_0b.jpg
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M;5:?]5";A.'$.M7Q-:JCJU1'5JH.KT#_J[A\3%-P4X_7 @        !) L+
MAJH"?4JP-MQ;&>&M#O-Z6!BV6!.&0\M4 >XJ_Z6J8QO5-V)T>%T
MD!@@#,R0UU)IY[67?#47?307=JMI"L.QU;@P'%BL\ENH.KY.77@+M $
M  "0+B ,#"A(U<7L547MU7 E#/L6J/:ZJ2X<U.BT,+<!        D"(@#+30
M**G48'7,?DWT/@TF#.%LA6'_HOO"X.NJ/+!"U5 -S@        !(#A"&IE'6
M4?%'5;$'-/P)@\]\I?<\>641. ,        @+4 8FD!1IX\_(HOSYUT8=LU5
M[IR#G $64 (        D! B#-9 M7#E2'Q\@%T88O&<K/6?+%?5PG@$
M  "0"B ,%J'TAN03-5<"ZN(#!#K#@(1AYRRE]UPYWA4         $ D0!HND
MGZM).%@MO##LF*$\OEF)]P8         Q "$P3Q%UV4)!RNL"$,DG\*P?88\
M)PWV9P        #$!X3!#%J5/O%(*4_"<-"*,,RY+PR>TY4[IL&%20
M (#X@#"8X69$V=5#)2R$(9@[8=@V37DE1(OW#         "$!80!1UFO33I4
M( 5AV#8#3C(         (@/"@)-QOB3Q<"%=8=C%HS!LG:+,3H-M&0
M   Q 6%X"$I/)1\K^$L8RL41AID/A&'W?!7>10         0$!"&ARBX5IEX
M.,]68=C,F3!LF0I7)0$       !B L+P$.FG<YL0!C^6PG!T%2MAF*PLRH2K
MD@        #1 &%XB)3C62R$(6PGC\(0N$.-]Q(         A *$X0&R2D72
M$5(8:GD4AH46A6'[7\*P!39D         ,0#A.$!1=<JN!2&C=P(P]8I( P
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M,'@1PK 9-GL&        Q$,X8= 4>=$1!IVB!&\I%.GG<B4H#+ / P
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M%@8CE*9"4WY6G>^CRM^CK8Y#_XW?0R3DU2IVPA"Z@WMAV#9%KE;@/00
M    (1%'&*1,RLD"0A@:1!&&_<M %P        "1 6' *;]3SYDP;& O#%NG
MR^NJ8+HS        (#(@#&9(.4Y#&'S9"L,R6L)P>(,*[Q8         " X(
M@QFJ\Q0)AXO8",,VCH1AIEP'NR\         $@"$P3PWSE=@PA#GSZ,P^+H^
M$ ;/6?);"3J\0P         @!B ,YM%KJ:1CW C#B;7,A"%HEQKO#0
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M"$.HKSHK18]7Y)GZ&NK(%M7,7@U3>\JF_""C(PRF3.W9$+A;K=7 9P$
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M&(*$%0:E7'QAF-+#_K9B &$      $: ,-@C]0WR?W>=;'QID E,G.=IFL^
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M0O)MO+HY0!B80E,8BDNK\):29-7FHV3G&>79M@-=IGJ</!?;(*-U249-;4/
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M0L-CK_?A::J5">D* Z655<;-*;\PLDEAR M959UQ 6_/A/1SZ:R%(<);K=.
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M_ D]J)G56]Y8&*;8)@PH*\?Q,@=?2$ 86-"M/ZUQV/?]7?&6DN3 L0MDY\F
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MC5>W 'IOA$8FCYFQA>EB3606KMZ/5^>3N\)@T)3H4_Y." #3W!4&JF05?@1
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MSK-M!\Y:["-7J/ ^B0<( ]!" 6$0A;5;CS_;5KC+0Q]OXS37?4]=O1SOQSU
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M7TK!NP4 O"&:,,@3^S$7AHE-"D,.(0S*JG+\V%P0?]#\I&?.A:&RF,?-J@$
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MD5_(RY75 , (T82!TFMDL=];%H:!G B#HJH,/S!W7#FFY548/*?)=?!K @
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MBJ^.'LQ0&!8^$(;SFY65>7A182F^K0OQ4M 1AH,/"\/^A8H[B;Q/T08
M    IDA(& QWYT#7RC+65$09A6$P?6&H3 _2:R5QZ;]>9[@5K0O:K*0I#/Y+
M% E!6K@,"0       ) FTA(&(SI93OV-#551OS8I#/FA2ZO2 [6*&KR$V"!M
MR$O5Q9U4!VY4FA6&PRL4D0'JVPF@"@       ("DD:(P&*&T,E79Y?I;/M57
MEU9<FO&7,$PIO;2HXLK6VHQ 1=EU7C=RYHJ&*JKXCCXW39>;JLM)U15GZ>LJ
B*/Q.         "!)_A^6L1,=D>"BX@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139886347999184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Aug. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  09,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
MFS@-60=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " ";. U9B'&K9^\    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " ";. U9F5R<(Q &
M  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( )LX#5G>][,X%@4  ',6   8              " @0X(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " ";. U9GZ ;\+$"
M  #B#   #0              @ %:#0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( )LX#5F7BKL<P    !,"   +              "  380  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( )LX#5D9117U-P$  "<"   /              "
M 1\1  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " ";. U9)!Z;HJT   #X
M 0  &@              @ &#$@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " ";. U999!YDAD!  #/ P  $P              @ %H
L$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  "R%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20240809.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="huma-20240809.htm">huma-20240809.htm</File>
    <File>huma-20240809.xsd</File>
    <File>huma-20240809_def.xml</File>
    <File>huma-20240809_lab.xml</File>
    <File>huma-20240809_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "huma-20240809.htm": {
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20240809",
   "dts": {
    "inline": {
     "local": [
      "huma-20240809.htm"
     ]
    },
    "schema": {
     "local": [
      "huma-20240809.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "huma-20240809_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20240809_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20240809_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://www.humacyte.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "huma-20240809.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "huma-20240809.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, par value $0.0001 per share",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50",
        "label": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001818382-24-000153-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-24-000153-xbrl.zip
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M2\6(CLM/ZZ 4,?7^T+5K.GD-:<HH7XA/X QS56^E,=<J=<Z[/[VZ8IQ]BB&
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M93-G,M.$6I\7-WE=WI\7B9XG#!.-N((A5F82B3"&,<4!Q B%2H@T9(H.T>%
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MI;:^<5XLET6^M@]1 Y%OXC6X+C/5!/V$T(LP<#/3W3H/,U#OZKD)=0T#OJZ
MCNB7G02.Y)&[N2?UQ4Y:3[VP.\BWA?/V[L)DJS*[1%RUS.=*(J*TD6D0*:/5
M)"!0,F.$@1;&'34/&>9N?9LVR#3-FK=WX!$8K)!=FS,=!1K:D1E'VZL-X\38
MH^W23VE$KZ4CZ<0-EGY:[:[*GEA?$;Y)$O/25N?FX<?RHKC-YUA%24*Q$1V1
M(:01PE"*",,P(0EA28QYY-94:6-,(\$U['-@@6U#T$*[:K!=GZ$2',7:2X%N
MA#TDV$MIA +;.2<68"^IMO[Z0SW6@,4B4T;)^>7O9H%99F)A#E/"&.5081U
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MEJUFWO&[6[U,CK5GJ95_VBU+??1:.Y9Z ]W=Z,U2YXF]@O3;0ES.F48$,9G
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MEF]9#H[":M^"!+KV\Q8 2P2*!84QM^F!UT5SZWA3S P('=YZ(UBHF7,9;NP
MH@2KC1@0GYT*NZ$0#C'IBW:A:8\FTE-J%[)9X&F=W<SVTNDO8$ZSM;:JNPKV
MQV1DY;6]AC31$%M%V^HVNG,04;QH*B_/$!+('/75*8ID;\-]Y)[(*%1P73L:
M"8$7(/]?L4CC:&[VR2@E#GG]X(Y^:%QG%#LE7 .J5QWDKDJLABUP$H7BVK5?
M'9:[R8%8+-!NH807$H?-0JUF*FCFR$7VDD(#LK4*\.X^.)"99VG<C-2:D> !
M%-"*@2==#;-DZVQ8LQ"2^#_513L(3\1W!B*P8649K@NS*(@"?@*+YFF\](:I
M'M;YAL)]<)1S.3>CQ) 5SL,(SW=VL;M$:BN&8:R@)Z:-,W5T8J81:W VXT:/
MG,)3<+&*.XFZ!&Z(?K<'Y#!/)V=A-"I LIH?<@)"N86+!:#F/$?$0P, L^=G
M/-R@@Y]Q*CO1+7W^3R?Y+]!)WNZW-S+%;@+(HV>?WX?YDI6@K;P+);>2LFM<
M#@\2V9#Q!8L6)(ISUG:L%:>ZT^A39_S+-IR") U9NC +UKLECIO9;5=1MERR
M"?(4.4FBZU;W"<<@L02%NM%NP GNQ)7F$8/NP+X=>-:_MN9H'90-%#O%A6T3
MTZMKR'BS-J^=V[:^D:"IS,^4TB@(S3E3)+"B1ECJC@Q4<?I/WB'3US#S*4V6
MX/!.5.Q&#<DR@!ME+?DWD#@<<S.!&;S%E]8V4HP&7+JV^RZWN]U&\E" +^JX
M&;8()IQF]KQ+ON-$,JFVF9)%I\U2% U/4@,IRJ]T E&!-K$'9S36G+@#FN.U
MK3Z;RUSL<[M>F'UO:[-;]][J#FB7&R(S!0?X "TI9FZ<RR?EY$0SN>"@QM/>
M%6"X8&6LU4%FNB.Y'%H0>6*JM]%$J4P2!\0TY#<*+M?D.NJU$L VGL?4C(N=
M5.WFV[R[[ 8R.\C4M0N($T F9*]1I:?TFYE<:2&X4Y[Z#,'=!QR%=)VO"!$>
M",#J411$XP]NI@/B_89J=:-A_Q]M)KQ4\'0(=W%!.QR_/^KY 7G(J,.YI0S7
M;6CCQ]?GJ[DN=NOT*DCU0+RCZ> VL@P1 TD17+^EBEYG7+JM)E <4QFG<;26
M9$+#';/,^2@9P8&;4:04'!1+OJ8,78E'/.-EON>=MGN.EH'IJ_%%Y#@9_]:K
MMV!=.5^7[C; W0V%RY%<'N('+F<\8'TK"+,< Y+FKLQ212-Q5$I;^B!K+=>&
M)[ \>.SB2%9S']^R'!A66R[ALN-@ T9*@A-H\AI(<8$XIX%)F?L F6/[@7A]
M0^9)=*?F 0*4JM?&K(4)H2"//1?!E/+@D!L/;(>;?ZO1&HC_;^G&+*M4PGQW
M-(1NFJ\3WT'O21J<+M4A^0OE"52=IF@0)LX"33_L2@"'XN06T!YE1:-5U=#D
M%N>4'$3K3:Z'"WTH,ON[62)(F609(FE%+RYUHCY&FHJ4VI)AN+P\I_?_.^H?
MCH[ZX_V#_N'A<*\;U>V .$G^8(COZJ']+!T*WST]')_1O*M%3.%1H&+?GT/=
MQT0A'28KF$1IIQ#ZN)6%RN;R$6C*!TJ)+YLH577-FD(M$$V_8B(^^@A46:\I
M\-']X_%!?_]D;_S8Y* "'BP"98#?MN#_1U.(0M0BE?^VEMS^O?-[_5L,#U!)
MN%>]X(7[AT%>\#](\B]02P,$%     @ FS@-64_8X^);*   +Y<! !@   !H
M=6UA+3(P,C0P.#$S>&5X>#DY,BYH=&WM/6ESX\9RW_,K)KN.(U5 FN!-R7:5
M5MJ-U]DKVK5=^?1J" S%>0(!& >U?+\^W3V#@R1(D13%2TBJ_%8D,9CI^YKN
MGX?1R/GUYZ'@]J__]O._5RKLQK/BD7 C9@6"1\)F<2C=._:7+<)[5JGH7UU[
M_B20=\.(U6OU)OO+"^[EF*OO(QDYXM=DG9]_4G___!.]Y.>^9T]^_=F68R;M
M7UY)JR/,QJ#?J0NKV;0'_5ZOW:M;@S87_=J@,[#_8;Z"1^'GZIDPFCCBEU<C
MZ5:& M]_T6SYT>6#M*/AA5FK_<>KZ=_QX Y^&GG^A5GW(_ARX+D1;"* 1=4_
MU=KS;\@]68,W1.)[5.&.O',OZ-QZJ>3GEN=XP<7K&OW?)7Y3&?"1="87__E-
MCD3(/HD'=NN-N/N?1LC=L!**0 [4#T/Y+Z%>0G\^J'-U8!U'NB(YIUG'P[W]
M/I1]&;%>KUJ?/L%J>[< (R* S<O1'>-.!!@8\3OQCUKUG_[=*Q8&UNPG:DF]
MB7;#_WZIE^][4>2-+A#\8Q%$TN*.?@F]3WVM,=-HM/WOA8C,;;6]8*MY./>Y
M=7\7>+%K5S3(!_1_ETL0<!5([BP">WTEL/\6C[@UB01+8+XB[K?PZJ_"\ER[
MZ+U[@@7[WY@'@!G%^>^DRUT+%F6W(HR=*&3<M=D;%!HB#-D?O@U"9"5*K:^
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M(1R'(T$JR"&M IS2WW^!S?KXC,.ND&$G[$:& J"[?;!Q_/]-P+94TE2N/7<
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M^ENM878;]6;K?#8^H1P4<.C #0W9V=6?Y]JGG?9JO&F_5PD\>JEV/RG&I2)
M8W R*5134?QM,)!N-IC1:)EG89\HMLFKJS?KTSYU^E(M=_\ [PV>_ KND( W
M?^%8,R%!I*.WA>ZT6A[#8XE8!&&KW4TF)/GWZ9GA5.#/7?W)!J"$0)S3.0M\
M>B5G8?6^H.B5YSC> ^8!X.>QCV^H-QE%U4+R>/$%! MCL6.=.)3+?&O0>:'\
M3F\WZ_H%[,SR*GX@1Z@%P+'W/0F'__%UJU><2WJR=[AF4M;?AS73-B]K5:!
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M[N>$^]/(<>(%GB$0'0R<#L#M/-<%G,#G(7?&F-2=DP8Y'.&/ 4>$&H)^WH<
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MSW PB#$(180EK!DW%_ O BKW@\ ;"&JV :@<"+&Z"5ERQS+N^$SFABM0!%+
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MBV, 1W>4P (1U?L,OI'*1<A-#$49CI&R)<C6U*E?0)A..C_E?J6GR[) AO=
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MYD'PJ,Z':!C!UBP]24-I*JQK\$;2,E(2(.S]^+K9N?24:A61ZJZJI6E>SRT
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M^?7_ 5!+ 0(4 Q0    ( )LX#5F? 2^,$A$  )Q\   1              "
M 0    !H=6UA+3(P,C0P.# Y+FAT;5!+ 0(4 Q0    ( )LX#5F:)+<*E@(
M /T(   1              "  4$1  !H=6UA+3(P,C0P.# Y+GAS9%!+ 0(4
M Q0    ( )LX#5E3F+RWBP@   ,^   5              "  084  !H=6UA
M+3(P,C0P.# Y7V1E9BYX;6Q02P$"% ,4    " ";. U9\2E_B.<,   (;0
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K82TR,#(T,#@Q,WAE>'@Y.3(N:'1M4$L%!@     '  < TP$  "UM      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>huma-20240809_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20240809.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-08-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
